Edition:
India

Fresenius Medical Care AG & Co KGaA (FMEG.DE)

FMEG.DE on Xetra

70.74EUR
20 Mar 2019
Change (% chg)

€0.56 (+0.80%)
Prev Close
€70.18
Open
€70.14
Day's High
€71.92
Day's Low
€70.12
Volume
851,126
Avg. Vol
1,021,321
52-wk High
€91.74
52-wk Low
€55.44

Summary

Name Age Since Current Position

Dieter Schenk

66 2018 Chairman of the Supervisory Board

Rice Powell

64 2013 Chairman of the Management Board, Chief Executive Officer

Ben Lipps

79 2013 Honorary Chairman

Rolf Classon

74 2018 Independent Vice Chairman of the Supervisory Board

Michael Brosnan

64 2010 Chief Financial Officer, Member of the Management Board

Olaf Schermeier

47 2013 Member of the Management Board, Chief Executive Officer for Research and Development

Harry de Wit

57 2016 Member of the Management Board, Chief Executive Officer for Asia-Pacific

Katarzyna Mazur-Hofsaess

56 2018 Member of the Management Board, Chief Executive Officer for Europe, Middle East and Africa (EMEA)

William Valle

59 2017 Member of the Management Board, Chief Executive Officer for North America

Kent Wanzek

59 2010 Member of the Management Board, Chief Executive Officer for Global Manufacturing and Quality

William Johnston

74 2006 Independent Member of the Supervisory Board

Pascale Witz

52 2016 Independent Member of the Supervisory Board

Gregor Zuend

60 2018 Member of the Supervisory Board

Dominik Heger

2016 Senior Vice President

Biographies

Name Description

Dieter Schenk

Dr. Dieter Schenk has been Chairman of the Supervisory Board of Fresenius Medical Care AG & Co. KGaA since May 17, 2018. He was Vice Chairman of the Supervisory Board of Fresenius Medical Care AG & Co. KGaA from 1996. He is Vice Chairman of the Nominating Committee at the Company. He is an attorney and tax advisor and has been a partner in the law firm of Noerr Stiefenhofer Lutz since 1986. He has been Member of the Supervisory Boards of Fresenius Management SE (Vice Chairman), Fresenius Medical Care Management AG (Vice Chairman), Bank Schilling & Co. AG (Chairman), Gabor Shoes AG (Chairman), Greiffenberger AG (Vice Chairman, until May 7, 2017) and TOPTICA Photonics AG (Chairman).

Rice Powell

Mr. Rice Powell has been Chief Executive Officer and Chairman of the Management Board at Fresenius Medical Care AG & Co. KGaA since January 1, 2013. Prior to that, he served as Deputy Chairman of the Management Board at the Company and Chief Executive Officer of Fresenius Medical Care North America from January 1, 2010. Previously he acted as Member of the Management Board of Fresenius Medical Care AG & Co. KGaA, Chief Executive Officer of Renal Therapy Group of Fresenius Medical Care in North America. He has been representative of Fresenius Medical Care Management AG, general partner of the Company. He joined Fresenius Medical Care in 1997 and was appointed co-CEO and Member of the Management Board of Fresenius Medical Care North America on January 1, 2004. Mr. Powell has experience in the healthcare industry. From 1978 to 1996 he held various positions within Baxter International Inc, Biogen Inc, and Ergo Sciences Inc, the United States, among others. Mr. Powell is also Member of the Management Board of Fresenius Management SE and of the Board of Administration of Vifor Fresenius Medical Care Renal Pharma, Ltd., Switzerland.

Ben Lipps

Dr. Ben J. Lipps has served as Honorary Chairman of Fresenius Medical Care AG & Co. KGaA since January 1, 2013. After earning his Master and Doctoral degrees at the Massachusetts Institute of Technology in Chemical Engineering, Dr. Lipps led the research team that developed the first commercial Hollow Fiber Artificial Kidney at the end of the 1960s at DOW Chemical. Dr. Lipps has held the position of Chairman of the Management Board of Fresenius Medical Care Holdings Inc., USA and Member of the Management Board of Fresenius Management SE. He has also acted as Member of the Board of Vifor Fresenius Medical Care Renal Pharma Ltd.

Rolf Classon

Mr. Rolf A. Classon has been Independent Vice Chairman of the Supervisory Board of Fresenius Medical Care AG & Co. KGaA since November 30, 2018. He was Independent Member of the Supervisory Board at Fresenius Medical Care AG & Co. KGaA from May 11, 2011. He is Vice Chairman of the Audit and Corporate Governance Committee and Member of the Nomination Committee and the Joint Committee at the Company. He is Member of the Supervisory Board of Fresenius Medical Care Management AG as well as Member of the Board of Directors of Hill-Rom Holdings, Inc., U. S. (Chairman), Tecan Group Ltd., Switzerland (Chairman), Catalent, Inc., U. S. (Non-Executive Director) and Perrigo Company plc, Ireland (Non-Executive Director, since May 8, 2017).

Michael Brosnan

Mr. Michael Brosnan resigned as Chief Financial Officer and Member of the Management Board at Fresenius Medical Care AG & Co. KGaA with effect from December 2019, a position he has held since January 1, 2010. He plans to retire from the Company after his successor has been identified and transitioned into the role, which is expected by the Company by the end of 2019. Previously, he served as Chief Financial Officer of Fresenius Medical Care North America for seven years. He joined the Company in 1998 as vice president of Finance and Administration for Spectra Renal Management, the company’s laboratory services organization. Subsequently, he assumed several executive functions at Fresenius Medical Care North America. Prior to that, he held senior financial positions at Polaroid Corporation and was an audit partner at KPMG. He has acted as Member of the Management Board of Fresenius Medical Care Holdings, Inc., U. S. (Member of the Board of Directors) and Member of the Board of Administration of Vifor Fresenius Medical Care Renal Pharma Ltd., Switzerland.

Olaf Schermeier

Dr. Olaf Schermeier has been Member of the Management Board and Chief Executive Officer for Research and Development at Fresenius Medical Care AG & Co. KGaA since March 1, 2013. Dr. Schermeier serves on the Supervisory Board of Xenios AG. Prior to FMC-AG & Co. KGaA, Dr. Schermeier served as President of Global Research and Development for Drager Medical, Luebeck, Germany. Dr. Schermeier has many years of experience in various areas of the health care industry, among others at Charite clinic and at Biotronik, Germany.

Harry de Wit

Mr. Harry de Wit has been Member of the Management Board and Chief Executive Officer for Asia-Pacific at Fresenius Medical Care AG & Co. KGaA since April 1, 2016. He has worked in various areas in the medical device industry for over 25 years. Previously, Mr. de Wit served as President Asia at Covidien (now Medtronic) in Singapore. He holds a Master’s degree in Medicine from the VU University of Amsterdam, the Netherlands and a Bachelor’s of Science in Physiotherapy from the School of Physiotherapy of Den Bosch, Netherlands. Mr. de Wit has been Non-Executive Member of the Board of Directors of New Asia Investments Pte Ltd. since March 25, 2014.

Katarzyna Mazur-Hofsaess

Dr. Katarzyna Mazur-Hofsaess has been Member of the Management Board, Chief Executive Officer for Europe, Middle East and Africa (EMEA) of Fresenius Medical Care AG & Co. KGaA since September 1, 2018. Before joining the Company, she had been President for EMEA at the med-tech company Zimmer Biomet since 2013. She has 25 years of professional experience and held various positions in the medical and pharmaceutical industry from her positions, among others at Abbott Laboratories and Roche.

William Valle

Mr. William (Bill) Valle has been Member of the Management Board and Chief Executive Officer for North America of Fresenius Medical Care AG & Co. KGaA since February 17, 2017. Prior to that, he was executive vice president responsible for the dialysis service business and vascular access business of Fresenius Medical Care North America from 2014 to 2017. He joined Fresenius Medical Care in 2009 and has nearly 30 years of experience in the dialysis industry, holding executive positions in sales, marketing and business development at several dialysis companies including Gambro Healthcare, Inc.

Kent Wanzek

Mr. Kent Wanzek has been Member of the Management Board, Chief Executive Officer for Global Manufacturing and Quality at Fresenius Medical Care AG & Co. KGaA since January 1, 2010. From 2004 onwards, he was in charge of North American operations for the Renal Therapies Group at Fresenius Medical Care North America. Prior to joining the Company in 2003, he held several senior executive positions at Philips Medical Systems, Perkin Elmer and Baxter Healthcare Corporation, among others.

William Johnston

Mr. William P. Johnston has been Independent Member of the Supervisory Board at Fresenius Medical Care AG & Co. KGaA since May 9, 2006. Additionally, he acts as Chairman of the Audit and Corporate Governance Committee and Member of the Joint Committee at the Company. He is former Chairman of the Board of Directors of Renal Care Group, Inc. He is also Operating Executive of The Carlyle Group L. P., U. S., Member of the Supervisory Board of Fresenius Medical Care Management AG as well as Member of the Board of Directors of The Hartford Mutual Funds, Inc., U. S. (Chairman) and HCR-Manor Care, Inc., U. S. (Non-Executive Director).

Pascale Witz

Ms. Pascale Witz has been Independent Member of the Supervisory Board of Fresenius Medical Care AG & Co. KGaA since May 12, 2016. She is Member of the Audit and Corporate Governance Committee at the Company. Ms. Witz was Executive Vice President of Global Diabetes and Cardiovascular of Sanofi S.A. as well as on Sanofi’s executive committee (equivalent to management board), prior to which she held other executive positions in Sanofi S.A. and with GE Healthcare and Becton Dickinson. Ms. Witz has served on the Board of Directors of Regulus Therapeutics Inc. since June 1, 2017, Horizon Pharma plc since August 3, 2017, Perkin Elmer Inc. since October 30, 2017 and Tesaro, Inc. since May 5, 2018. Additionally, Ms. Witz is President of PWH ADVISORS SASU, since November 2016, and the founder of PWH ADVISORS LLC, since May 2018.

Gregor Zuend

Prof. Dr. Gregor Zuend has been Member of the Supervisory Board of Fresenius Medical Care AG & Co. KGaA since October 29, 2018. He has been Chief Executive Officer of the University Hospital of Zurich since 2016. As Director of Research and Education he has been Member of the hospital’s Executive Board since 2008. In parallel, he has been Managing Director of the Center for Clinical Research and Head of the Surgical Research department at University Hospital Zurich. Until 2001, Prof. Dr. Zuend was senior physician at the clinic for cardiovascular surgery at University Hospital Zurich. He spent several years at Texas Medical Center, Houston, and at Harvard Medical School, Boston. Prof. Dr. Zund is Professor ad personam at the University of Zurich. He holds Doctorate of Medicine degree from Universitaet Bern.

Dominik Heger

Basic Compensation

Name Fiscal Year Total

Dieter Schenk

125,000

Rice Powell

7,292,000

Ben Lipps

4,862,000

Rolf Classon

122,000

Michael Brosnan

2,874,000

Olaf Schermeier

2,057,000

Harry de Wit

1,745,000

Katarzyna Mazur-Hofsaess

1,447,000

William Valle

5,210,000

Kent Wanzek

7,522,000

William Johnston

127,000

Pascale Witz

143,000

Gregor Zuend

25,000

Dominik Heger

--
As Of  31 Dec 2018